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Abstract 
Primary brain tumors consist are a 
heterogenic group of malignancies. Gliomas 
represent subtypes which include all 
tumors arising from glial cells. The risk 
factors for gliomas are until today unclear. 
The aim of this study was to summarize all 
possible connections between suspected 
risk factors and glial brain tumors. 
Introduction 
Primary brain tumors consist of a 
heterogenic group of malignancies. They 
have a relative small incidence when 
compared to other neoplasms. Their 
incidence varies according to different 
classification techniques used. According to 
Central Brain Tumor Registry of the 
United States (CBTRUS), in 2004-2008, 
their incidence in the US was 19.89 per 
100,000 person-years (1). In the 
GLOBOCAN 2008 series published by the 
International Agency for Research on 
Cancer (IARC), brain tumors represented 
1,9% of all cancers excluding non-
melanoma skin cancer (2)*. In the 
CBTRUS statistics, gliomas represent 30% 
of all primary CNS tumors and 80% of 
malignant ones (1).   
Epidemiologic studies offer the 
possibility of understanding how a disease 
acts and who, when, where and why is 
exposed. They constitute the basis of 
understanding a disease and offer a chance 
on preventing and treating it. 
Epidemiologic studies concerning risk 
factors for gliomas have studied a multitude 
of possible elements, but their results until 
now have been mostly inconclusive. This is 
due to the small number of cases, to the 
heterogeneity of study designs, inconsistent 
approach to suspected risk factors. The goal 
of this review is to provide up to date 
knowledge concerning risk factors for 
gliomas and offer an overview of 
epidemiologic literature data available for 
glial tumors.    
Material and methods  
This article includes data from studies 
indexed by MEDLINE. We used the terms 
“brain tumors” or “gliomas” in combination 
with “epidemiology” or “risk factors”. All 
articles, including reviews were covered. 
Articles published in the last five years were 
the first used when discussing a certain 
topic. When not available, older articles 
were included. All related abstracts to those 
initially used, were included. Three large 
epidemiological reviews were extensively 
used in order to create specific categories of 
risk factors (3-5). We have to mention that 
our search did not exclude articles cited by 
these reviews. We also have to state that we 
used data from experimental research in 
order to highlight certain facts. For every 
category of risk factors the terms (e.g. 
ionizing radiation) combined with “brain 
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tumors” and “gliomas” were again searched 
for on Medline.   
Age and race 
Brain tumors affect more Caucasians 
than African or Asian descendants, this 
being true for all ages (4). The CBTRUS 
report indicates that whites are affected 
twice more frequent than blacks. Also, for 
all brain tumors, whites are affected more 
frequent than Hispanics. The incidence in 
Japan is half of that seen in Northern 
Europe (3). 
Age-adjusted incidence tends to be 
higher in developed countries (4). For 
gliomas the peak incidence is situated in the 
75-84 years interval (1). Age-adjusted 
incidence rates follow an ascending route, 
except the decrease in incidence in the 85+ 
years (1).  
Gender, hormonal status, exogenous 
hormones and risk for developing gliomas. 
The fact that glioma incidence varies 
according to gender is now admitted by 
most studies. Given the fact that gliomas 
are less frequent in women, their age at 
diagnosis is higher, researchers have tried to 
study a possible link between female gender 
and gliomas (3). Data available from the 
CBTRUS shows a higher incidence in 
males than females (7.17/100 000 person-
years vs. 5.07/100 000 person-years) (1). 
According to the same registry, gender is 
also important in survival, with females 
having longer survival rates for most types 
of tumors, except brain stem and pineal 
glands. While age alone should not 
disqualify patients from receiving complete 
treatment (6), a study found that women 
were older when diagnosed than men, and 
this was contraindication for treatment after 
surgery (7). Data from GLOBOCAN 
shows a higher incidence of new cases of 
brain tumors in men vs. women (127000 vs. 
110000) (2). The number of deaths due to 
brain cancer is smaller in women vs. men 
(77000 vs. 97000) (2).    
 Experimental research, in which rats 
were transplanted with glial tumors, 
showed a slower rate growth in female rats, 
a longer survival for females and for the 
group estrogen treated group (both males 
and females) (8). 
 A review of current knowledge between 
hormonal status and gliomas, published in 
2010, included 15 articles concerning 
gliomas. The final conclusion of the study 
is that female sex hormones are protective 
against gliomas and constitute risk factors 
for meningiomas (9). In contradiction, in 
the EPIC study no connection between 
feminine hormones and gliomas was found 
(10).  
An older age at menarche was associated 
with a higher risk of gliomas in the NIH-
AARP Diet and Health Study (11). This 
conclusion was also drawn by researchers in 
other studies to (9). The NIH-AARP Diet 
and Health Study found no other link 
between female hormones and risk of 
gliomas (11). Ever being pregnant had a 
protective effect in one study (12). Some 
studies also found pregnancy to be a 
protective factor, while others found no 
relation between the two (9).    
Research concerning the effect of 
exposure to exogenous hormones either by 
oral contraceptives or hormone 
replacement therapy and glioma risk had 
mixed results. Studies found a slightly 
higher risk (13), no influence (10, 14) or a 
protective role of this therapy (9). The later 
study combines conclusions from 15 
studies, and majority of these studies 
sustain a protective role of exogenous 
hormone therapy against gliomas (9). 
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Genetic risk factors – family aggregation, 
genetic syndromes and gene polymorphism 
The existence of a family member with a 
glioma, could represent a risk factor for the 
other members. Wrensch and all conducted 
a study were they showed that OR of a 
primary brain tumor (PBT) in family 
members of patients with PBT was 2.3 
(95% CI=1.0-5.8 (15).In a study of 
Malmer, the authors obtained similar 
results (16). The same author investigated if 
genetic factors or genetic ones were the 
cause of a higher incidence of brain tumors 
in families having one member already 
affected by the disease (17). The study 
revealed that standardized incidence ratio 
(SIR) among spouses of HGG patients was 
the same as in the general population, while 
SIR was 2.30 (95% CI=1.66-3.11) for first 
degree relatives of patients diagnosed with 
HGG (17).  Segregation analysis showed 
that family aggregation could explain only 
5% of glioma cases, and that a recessive 
gene model fits in about 2% of all cases (18, 
19). On the other hand, family aggregation 
wasn’t confirmed by a study in Iceland (20).   
There is strong evidence that some 
inherited genes influence the risk of 
developing a glioma. Some familial cancer 
syndromes are associated with brain tumors 
(4). The most important of these 
syndromes and the associated genes are Li-
Fraumeni syndrome (TP53 mutations), 
type 1 and 2 neurofibromatosis (NF1 and 
NF2), tuberous sclerosis (TSC 1 and 2), 
retinoblastoma (RB1), and Turcot 
syndrome (APC and hMLH1/hPSM2 
mutations) (4, 5).  
Li-Fraumeni syndrome is characterized 
by a familial aggregation of tumors, with 
about 70% of cases carrying TP53 
mutations (4). In the IARC database of Li-
Fraumeni syndromes, 14% of cases had a 
brain tumor, thus suggesting that familial 
gliomas could be related to p53 mutations 
(21). A study of 18 families with 2 or more 
cases of glioma, didn’t show any connection 
to p53 mutations, infirming this hypothesis 
(22). It must be said that these families did 
not meet classic Li-Fraumeni criteria.   
Neurofibromatosis type 1 is an 
autosomal dominant disorder characterized 
by cafe-au-lait spots and multiple 
neurofibromas and an increased incidence 
of diffuse astrocitomas, gliomblastomas, 
optic nerve gliomas (4). Neurofibromatosis 
type 2 is characterized by dysplastic and 
neoplastic lesions of the Schwann cells, 
meningeal and glial ones (4). About 80% of 
gliomas that occur in NF2 patients are 
tumors of the spinal cord and cauda equine 
(4). 
Turcot syndrome is also an autosomal 
dominant disease, characterized by colonic 
adenomatous polyps and nervous system 
tumors, usually meduloblastomas (23). 
Gene polymorphism has been 
intensively studied by researchers. Genes 
involved in DNA repair are probably the 
most studied category, because their role in 
preventing carcinogenesis (5). The 
methylation status of MGMT is not only 
involved in gliomagenesis but also it can 
predict tumor response to temozolamide 
treatment (24, 25). MGMT methylation 
together with microRNAs miR-21, miR-
181c, miR-195 are correlated to 
progression-free survival of GBM (26). 
MGMT F84L has been proven to be an 
important risk factor for gliomas (27). 
Individuals carrying wild-type genotypes of 
MGMT F84L and PARP1 A762VA, 
exposed to ionizing radiation have a much 
higher risk (27).A genotype, rs1760944 GG 
of APE1/Ref-1 promoter, involved both in 
DNA repair and redox activity, has been 
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show to exert protective roles in 
glioblastomas (28).  
A genetic variant of the CHAF1A gene is 
linked to an increased risk of disease (29). 
An AA or AC variant of the 8092 nucleotide 
of ERRC1 was 4.6 times more frequent in 
individuals with oligoastrocytoma (30). 
Another study showed that individuals 
homozygous for ERCC1 c8092a and 
ERCC2 k751q have an increasd risk for 
gliomas (31). Other subtypes of ERRC2 
were also incriminated (g3). Chen 
identified that carriers of the two “CGT” 
haplotypes of Vascular Endothelial Growth 
Factor Receptor 2 (VEGFR 2) in a Chinese 
population had a 42% reduced risk of 
developing gliomas compared to noncariers 
(32). Other genetic variants of four genes -
rs4295627, a variant of CCDC26, 
rs4977756, a variant of CDKN2A and 
CDKN2B and rs6010620, a variant of 
RTEL1- were associated with glioma risk in 
a female population (33).  
 Tayrac and all identified a 4-gene 
signature (CHAF1B, PDLIM4, EDNRB, 
and HJURP), that strongly correlated with 
survival of HGG patients (34). But this 
thesis needs to be verified, since it has been 
proven that susceptibility variants published 
in glioma Genome-wide association studies 
(GWAS) are different between GBM, low 
grade astrocitomas or oligodendrogliomas 
(35). 
Exposure to ionizing radiation 
Ionizing radiation is the only 
carcinogenic agent that has been classified 
by IARC as being a certain risk factor for 
brain tumors. Studies have shown increased 
incidence of gliomas or PNETs in children 
that received prophylactic CNS irradiation 
for acute lymphoblastic leukemia (4).  
Various studies conducted to observe the 
effects of ionizing radiation on children 
treated for tinea capitis found that risk for 
gliomas increased immediately post-
radiation, being higher even after ≥ 30 
years, dose related, with no relation to 
gender or origin (4). 
Different studies have analyzed effects of 
ionizing radiation after the exposure of the 
Japanese population to atomic bomb 
irradiation in Nagasaki and Hiroshima (3-
5). They all found an increased incidence of 
all brain tumor types, including gliomas. 
One study from Hiroshima found a direct 
relation between risk and the distance from 
explosion epicenter (36). 
TABLE I 
Gene mutations, gene polymorphism, gene 
variants possibly implicated in glioma risk 
Gene 
mutations/gene 
variants/genotypes 
Relation to 
glioma risk 
No. of 
Ref.  
Tp53 Increased or no 
connection 
21,22-
mixed 
results 
MGMT 
methylation 
Increased risk. 
Predicts tumor 
response to 
temozolomide 
24,25 
PARP1 A762VA 
genotype 
Increased risk 27 
MGMT  F84L Increased risk 27 
rs1760944 GG 
genotype of 
APE1/Ref-1 
Decreased  risk 28 
CHAF1A - rs243356
 
Increased risk 
 
29 
 
ATR (MIM 601215) 
RPA3 (MIM 
179837) 
Could determine 
genetic glioma 
risk 
29 
ERCC1c8092a and 
ERCC2 k751q 
homozygous 
individual 
Increased risk 
 
31 
CGT haplotypes of 
VEGFR 2  
Increased risk 32 
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The effect of medical exposure to 
ionizing radiation is yet to be clarified. 
Various studies assessed effect of either 
occupational exposure to ionizing radiation 
by technicians, radiologists or low-dose 
irradiation for diagnostic procedures- dental 
X-rays, head and neck X-rays, or CT of 
those areas (37). An INTERPHONE study 
found an insignificant increased risk for 
meningiomas or acoustic neuromas, but an 
inexplicable statistically significant lower 
risk for gliomas after any kind of medical 
exposure (37). Another study found an 
increased risk in a population that 
underwent ≥3 CTs, but only in those with 
a family history of cancer (38). 
Electromagnetic fields and use of mobile 
phones 
Probably the most important debate our 
days, concerning risk factors for malignant 
brain tumors, lies in the use of mobile 
phones. Several authors and institutions 
have conducted multiple studies that 
frequently show mixed results, and, 
moreover, results from one study are often 
contested by others conducting research in 
the same domain. 
One of the most active organizations 
that published studies regarding the use of 
mobile phones is the Interphone Group 
that functions under the Auspices of IARC. 
Their international study comprised 2708 
glioma and 2409 meningioma cases, from 
13 countries (39). The authors found no 
link between either glioma or meningioma 
risk and the use of mobile phones, even 
after 10 years of usage. The Interphone 
study found only a higher risk for gliomas 
in the temporal lobe, and for those subjects 
that reported repeated use on the same side, 
but the CI varied in very large limits. The 
OR was 0.81 (95% CI 0.70-0.94) in the 
regular mobile phone users group-defined 
by the authors as at least one call per week 
for more than six months. The OR was 
1.40 (95% CI 1.03-1.89) in the group that 
stated they used mobile phones more than 
1640 h. But the authors of the study argued 
that values for mobile phone use in this 
group, was very unlikely.  
The results of the Interphone study were 
extensively contradicted. In an article from 
2008, by Hardell and all (40) suggest that 
the results of the Interphone study are 
largely affected by bias, so that results could 
not be considered valid. Conclusions from 
the Swedish team of the Interphone Group 
that concluded that no relation exists 
between mobile phone use and risk of 
developing gliomas (41) were challenged by 
several researchers (42-44). Hardell 
conducted several studies were the 
researchers found a link between mobile 
phones and risk for developing severall 
types of tumors, including gliomas(45-48). 
In one study they found an increased risk 
for developing gliomas in people that used 
mobile phones for more than 10 years 
(OR=2.7, 95% CI 1.9-3.7), this risk being 
even higher in those  who started to use 
mobile phones before the age of 20  
(OR=4.9, CI = 2.2-11)(45). Another study 
of the same author found a higher risk 
(OR=3.4, 95% CI 1.6-7.1) for those who 
used mobile phones for more than 2000 
hours (46). A latency period of more than 
10 years was a risk factor for developing 
gliomas (OR=2.0, 95% CI 1.2-3.4), even in 
a meta-analysis were results were compared 
with 16 other studies (49).  
Results from five countries in the 
Interphone group, showed a higher 
incidence of gliomas in people that had a 
higher exposure to radio frequency fields 
(RF) from mobile phones (OR=1.91, 95% 
CI 1.05-3.47)(50). 
 
 
 
10          Florian et al          Risk factors for gliomas. An extensive review 
 
 
 
The conclusions of a long-term Danish 
cohort study published in 2011, was that no 
link exists between mobile phones and 
malignant brain tumors (51). This research 
updates information from a 2006 study 
(52), which in turn is an update of a study 
started in 2001 (53).  The results of these 
particular analysis were contested, partially 
for its design and extensive bias 
possibilities, and partially because the 
financing was done in part by companies 
that were involved in mobile 
telecommunications (54-56).  
In 2011, 30 scientists met at IARC, with 
the goal of establishing the impact that RF 
electromagnetic fields had on 
carcinogenesis. During that meeting, they 
established that RF magnetic fields are a 
potential risk factor for developing gliomas 
in humans (57). Their conclusions were 
based mainly on two studies, cited in this 
paper, one being the Interphone study and 
the other the study of Hardell and all. 
The conclusions of the IARC group 
were compared by Little and all with the 
effect of RF magnetic fields on glioma risk 
in the US population, based on 12 registries 
of the SEER database (58). The conclusion 
was that the US data, could be compatible 
with the information obtained in the 
Interphone study (moderate risk when 
mobile phones are excessively used) but in 
contradiction with the results of Hardell’s 
study.  
Finally we can say that the debate 
surrounding the influence of mobile 
phones on the risk of developing glial 
tumors is far from being over. In 2009, in a 
review of available data (59), Kundi stated 
that four epidemiological aspects should be 
taken into account when analyzing this 
subject: temporal relation (the exact time 
when a brain tumor appeared), association 
(assessed as possible counterarguments for a 
possible relation), environmental factors 
(risk factors that could coexist with mobile 
phone usage) and finally population 
equivalence (both cases and controls should 
come from the same type of population). It 
is almost impossible for a case-control 
study, and most studies so far have been 
done using this approach, to follow these 
guidelines. A final conclusion on mobile 
phones-glioma risk relation will come 
probably, only when researchers will create 
a new model for a possible study.   
Lifestyle factors 
There is still little evidence of an 
association between any lifestyle factors and 
an elevated risk for malignant gliomas. 
Although certain factors like alcohol, diet, 
smoking have proven to be in relation to 
certain types of tumors (colonic, rectal, 
breast, lung) studies up to day were unable 
to identify any relevant link between a 
certain lifestyle and brain tumors. The main 
cause is the fact that gliomas are not a 
common disease in the general population. 
This means that cohort studies cannot 
gather sufficient information, which in turn 
determines that data can only be collected 
from case-control studies (60). 
Diet and eating habits have not yet been 
proven to exert any certain influence on the 
development of gliomas. A study by Hu 
and all, in a hospital based case-control 
showed a relation between certain foods 
and gliomas (61). Consumption of fresh 
vegetables and fruits was inversely 
associated with gliomas (OR=0.29). The 
same effect was found for fresh fish. The 
consumption of salted vegetables 
determines a high risk for brain tumors 
(OR=2.54). This is explained by the high 
content of N-nitroso compounds (NOC) 
and NOC precursors. The study value is 
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limited, as it is a hospital-based case-control 
study of diet and by the low number of 
cases (73 glioma patients). A study 
conducted in California in 1997 among 
women with gliomas, also demonstrated a 
correlation between cured meat and an 
increased risk of gliomas, risk that was 
reduced by consumption of vegetables (62).  
Vegetable intake also decreased risk in 
another large cohort study (63).  
Two recent studies have shown that 
high coffee and tea intake are inversely 
correlated with glioma risk (64, 65). The 
first one reflects data from three 
independent cohort studies. Tea (more 
than five cups a day) and coffee reduced the 
risk for glioma (RR=0.60, 95% CI 0.41-
0.87). No association was found between 
decaffeinated coffee and risk of glioma, 
suggesting that caffeine has protective 
effects. In the second study, high coffee and 
tea intake (>100ml/day) were both 
associated with a significant lower risk for 
glial tumors. 
Vitamin intake, especially vitamins A, D 
and E was correlated with a lower risk for 
gliomas, both in population and 
experimental studies. Both food and 
supplement vitamins had this effect (61, 62, 
66). Retinoids, compounds related to 
vitamin A, have a significant anti oncogenic 
effect (66). Alfacalcidol, a vitamin D analog 
also has anti proliferative effects on glioma 
cell cultures (67). Tocopherols (vitamin E) 
also exert anti oncogenic effects on glioma 
cells (66). Dietary minerals, especially 
calcium and zinc, have protective effects 
against tumors, including gliomas (68, 69). 
No correlation between acrylamide, present 
in several heat-prepared foods and glioma 
risk was found by a study (70).   
Obesity and an increased body mass 
index (BMI) have been proven to be risk 
factors for gliomas in at least four studies 
(60). Obesity and it’s direct consequences, 
hyperglycemia and type 2 diabetes mellitus, 
were also found to be independent risk 
factors for a poor outcome in patients with 
HGG (71,72) while an increased BMI 
didn’t influence survival in another study 
(73).  
Caloric restriction may have an 
important role in improving outcome for 
gliomas (74). This is based on the fact that 
while normal glial cells can adapt their 
metabolism, tumor cells cannot do the 
same. Dietary restriction reduced 
angiogenesis in a orthotopic mouse brain 
tumor model and also in human glioma 
cultures (75, 76). Also normal nervous cells 
can use ketone bodies for energy, while 
tumor cells are highly dependent on 
glycolysis (77). This is the rationale for 
using a high-fat, low-carbohydrate diet 
(ketogenic diet) as adjuvant therapy for 
gliomas (77). The ketogenic diet also 
enhanced the anti-tumor effect of radiation 
in a study (78). Caloric restriction with 
glucose withdrawal could cause 
phosphorylation of AMP-activated protein 
kinase (AMPK), and this may cause 
apoptosis in astrocytoma cells but not in 
normal cells under similar energy stress 
(79). 
There is no certain evidence linking 
alcohol or smoking to an increased risk for 
gliomas. This is due to the small number of 
cases in different studies, the incomplete 
research hypothesis and deficitary patient 
selection (80). In the Melbourne 
Collaborative Cohort study, alcohol was 
associated with the risk for developing 
gliomas in a dose-response relation (81). 
But an older study from some of the 
members of the same team did not reveal 
any link between alcohol usage and gliomas 
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(82). A study by DeVito and all, showed 
that ethanol inhibited the stimulation of 
ICAM-1 (an adhesion molecule) by TNF-α 
(83). ICAM-1 is an important molecule in 
the neuroimune response, and it’s 
inhibition by ethanol, could explain a lower 
response of the CNS to injury, including 
gliomas (83).  
In a cohort study, Efird and his team 
found an increased risk for gliomas in 
smokers, marijuana consumers, and coffee 
drinkers (>7 cups/day) (84). A study on a 
population of 22.946 icelanders, also found 
smoking as a risk factor of cancer for all 
sites, except endometrium (85). Multiple 
studies did not find any relation between 
smoking and glioma risk (82, 86-88), while 
others have mixed conclusions (89). 
Alcohol and cigarette smoking are not 
currently considered to be risk factors for 
malignant brain tumors (90). A review of 
studies concerning marijuana smoking and 
risk for cancer did not find any increase in 
the risk for gliomas (91), but some studies 
support the hypothesis of cannabinoids as 
an effective adjuvant therapy (92, 93). 
Allergies, atopic conditions, infections, other 
disease, medication 
Allergies have clearly been indicated by 
most studies regarding this subject, as 
protective conditions against gliomas (94-
101). In a meta-analysis published in 2011, 
by Chen and coworkers, that included 12 
studies, authors conclude that allergies 
could significantly decrease the risk of 
gliomas (102). Moreover, some studies have 
shown that, the number of allergies for a 
patient is directly proportional with a 
smaller risk (98, 101). In a study risk 
decreased with 31-45% for every new atopic 
condition (98). Antihistamine usage was 
not correlated with this risk (101). In most 
studies the levels of IgE, an objective 
assessment tool for allergic conditions, 
correlated with the risk for glioma. The risk 
increased inversely with the levels of IgE 
(100, 103-105). It seems that function of 
immune cells is altered in patients with 
GBM, in the sense that instead of 
preventing tumor appearance, immunity 
mechanisms support it (106).  sCD23, a 
soluble marker, part of the humoral 
immune system, that enhances 
inflammatory response, is lower in GBM 
patients than controls (107). sDC14 that 
inhibits inflammatory response, is higher in 
GBM group vs. controls (107). Two 
subtypes of Interleukin (IL)-4 and IL-3 
were also associated with GBM, and OR for 
GBM were opposite of the ones for asthma 
(108). In a study, GBM patients having 
high levels of IgE survived 9 month longer, 
than those with normal levels (109). 
Autoimmune disease were also inversely 
correlated with GBM, in one study 
(OR=0.49, 95% CI= 0.35–0.69), the most 
significant being diabetes (96). Another 
study showed that patients reporting a 
previous infectious disease had a RR of 
0.72, 95% CI 0.61-0.85 of developing GBM 
(95).  
Until now some viruses of the Polyoma 
family, like BK virus, simian vacuolating 
virus 40 (SV40) and especially JC virus 
(JCV), have been proven to have oncogenic 
effect for GBM in experimental conditions 
(110). JCV proved oncogenic effect for 
malignant brain tumors in test animals. IgG 
antibodies to the capsid of      JCV, proved 
to increase OR for developing GBM to 
1.46, CI=0.61-3.5 in a group of patients 
(111). IgG for varicella zoster was inversely 
correlated with glioma and some studies 
reported multiple HCMV gene products in 
glial tumors when compared to normal 
tissue (5). VZV IgG levels were more 
 
 
 
Romanian Neurosurgery (2013) XX 1: 5 - 21         13 
 
 
 
 
common in glioma cases vs. controls in 
another study (OR=0.68, 95% CI= 0.41-
1.13)(112). 
Another condition investigated for a 
possible connection with HGG was 
epilepsy. A study found a 6-fold increase of 
risk for glioma in patients suffering from 
epilepsy in the last 2 years prior to 
diagnostic (95). The risk was highest for 
epilepsy for 20 years or less prior to 
diagnostic, although epilepsy > 20 years 
still had a higher risk. The Interphone 
Group also found a high risk of gliomas in 
patients with epileptic seizures (99). The 
authors conclude that seizures suggest a 
long preclinical evolution of gliomas, since 
they did not create two separate groups for 
low or high grade tumors. 
A family history of cancer could be a risk 
factor for developing brain tumors. A study 
found that risk of gliomas increases 1.4-3.4 
fold familial history is positive for stomach, 
colon, prostate or Hodgkin disease cancers 
(113). The authors found no connection 
between glioma risk and a family history of 
brain tumors. However a study from 
Sweden found an increased risk for gliomas 
for people who had a parent suffering from 
this disease (114). A family history of brain 
tumors also increased risk for 
oligodendrogliomas in a mixt Scandinavian-
US pooled analysis of 7 case-control studies 
(115). 
Non-steroidal anti-inflammatory drugs 
(NSAID) were correlated with a lower risk 
for developing GBM. In a study by Sivak-
Sears and all, GBM cases reported a smaller 
use of NSAIDS than controls (116). The 
findings were strongest for aspirin and 
ibuprofen. Another case-control study 
found a 33% lower risk for GBM in those 
reporting a regular use of NSAID (117). 
The authors failed in showing which 
NSAID had this effect. The influence of 
NSAID on gliomas, could be explained by 
the fact that they inhibit prostaglandins, 
inflammation mediators, that have a 
potential oncogenic effect (116). 
Angiogenesis, a vital tumor growth process, 
is linked to cyclooxygenase-2 driven 
inflammation, and this enzyme is 
irreversibly blocked by aspirin for example 
(116). 
TABLE II 
Medical conditions and relation to glioma 
risk 
Condition  Relation to 
glioma risk 
No. of ref. 
Allergies Decreased risk 94-101 
Increased IgE 
levels 
Decreased risk 100,103-105 
Autoimmune 
disease 
Decreased risk 96 
Polyoma virus 
infections 
Increased risk 
(experimenal) 
110 
Epilepsy Increased risk 95,99 
NSAID 
consumption 
Decreased risk 116, 117 
 
Occupation and environment factors 
Determining a relation between a certain 
occupation and the risk for brain tumors is 
difficult. In most professional areas, 
workers are exposed to more than one 
possible risk factor (3). It is hard to 
determine what is the total risk determined 
by all these factors together. For example, 
even if a certain chemical is proven to be an 
oncogenic agent, it’s interaction with other 
elements, could increase or decrease risk 
(3). Moreover, chemicals that have been 
proven to favor tumor genesis, had that 
effect on lab animals, where they were 
directly implanted. Their effect through 
another type of contact (touching, 
inhalation) could be different (3). All these 
things make it difficult to link certain 
professional factors with the risk of brain 
tumors. 
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A case-control study from Germany, did 
not find any association between a certain 
occupational field and the risk for 
developing gliomas. Authors studied six 
occupational sectors -chemical, agricultural, 
transport, electric/electronic, construction, 
metal- but found no significant risk in any 
profession (118). In the San Francisco Bay 
Area, physicians, surgeons, artists, foundry 
and smelter workers and petroleum and gas 
workers were at a higher risk for gliomas 
(119). A possible explanation is that health 
practitioners have raised access to diagnostic 
procedures that could explain some of the 
higher incidence (119). This is no longer a 
plausible factor because the access and 
quality of diagnostic procedures have 
increased dramatically. Also, medical staff 
has contact with a large number of agents, 
i.e. disinfectants, biological agents, 
radiation, that could lead to an increased 
risk (119). Parental work in agriculture, 
motor-vehicle related, electric domain 
determined an increased incidence in 
children in another study (120). This 
association was valid for both parents, while 
work in the textile industry was true only 
for mothers. A retrospective research found 
a positive association between children 
gliomas and father exposure to lead, 
cleaning solvents, pesticides from lawn care, 
during pregnancy period or immediately 
after birth (121). It must be noted that this 
study only took into consideration exposure 
resulting from hobbies, not occupational.   
Exposure to pesticides was largely 
investigated as a risk factor for cancers. 
Phenoxy herbicides were proven as a cause 
for malignant lymphoma and soft-tissue 
sarcoma (122). A hospital-based, case-
control study did not prove any association 
between insecticides or herbicides and 
gliomas, although women exposed to 
herbicides were at a much larger risk of 
developing meningiomas than those that 
were not exposed to these substances (123). 
Opposite results were obtained in a 
retrospective study from India, which 
showed that gliomas were much more 
frequent in orchard workers, residents or 
children playing in orchards that were 
exposed to numerous chemicals 
(chlorpyriphos, dimethoate, mancozeb and 
captan) for more than 10 years (124). A 
study of residents of rural zones from 
several US regions also proved that not 
washing or changing clothes immediately 
after applying pesticides constitutes a risk 
factor for developing gliomas (125). 
Occupational exposure did not increase rsik 
of gliomas instead it determined a higher 
risk of meningiomas (126). A study noted a 
higher incidence of gliomas in professionals 
of the following domains: IT, farm 
workers, financial, medicine, management, 
while it found a decreased incidence in 
childcare workers (127). A possible link 
between gliomas and physiological stress 
was also investigated, and found that major 
life events in a 5 years period prior to 
diagnostic, constituted a risk factor (128). 
Studies trying to find a connection between 
sociodemographic variables and gliomas 
found mixed or inconclusive results (129). 
Head trauma 
An association between trauma and brain 
tumors has not yet been clearly 
demonstrated. Although that there are some 
reports of a positive association, the relation 
is either non-significant or inconsistent (4). 
Associations have been made between 
perinatal or adult head trauma or combined 
perinatal and adult head trauma (4). In a 
study OR for gliomas following any head 
injury was only 1.2 (95% CI 0.9-1.5) in 
men, and lower for females (130).  In a 
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Danish cohort study, that included patients 
hospitalized for concussion, fractured skull 
or any other head trauma, the incidence of 
gliomas was the same as for the general 
population (131). Several authors reported 
cases that indicated head trauma as the 
cause of gliomas and its influence needs to 
be further investigated (132).      
Other suspected risk factors 
There have been several sporadic studies 
investigating potential risk factors for 
gliomas. Use of hair dye could increase the 
risk of bladder and hematopoietic cancers, 
but no association was found with glioma 
(133). High birth weight (>4000g) was 
associated with an increased risk for 
astrocytoma, and this risk was 19% higher 
for every 1000g (134). Birth anomalies or 
season of birth were not associated with an 
increased risk for glial tumors (135). 
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